Journals / Gülhane Tıp Dergisi / 2004 / Cilt: 46 - Sayı: 1

Serum BNP levels in children treated with doxorubicin for their solid tumors

Doksorubisin tedavisi uygulanan solid tümörlü çocuklarda serum BNP düzeyi

Pages
38–42
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, it was concluded that it is necessary to increase number of the patients enrolled to the study and followup the cardiac functions.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Antracyclines have been used for a wide variety of childhood solid tumors.
📊
Key Findings & Data:In this study, we detected cardiac functions of 22 children with solid tumors who had received cumulative doxorubicin doses of 120-450 mg/$m^2$ by echocardiography and detected the serum BNP levels.
💡
Conclusion & Impact:However, it was concluded that it is necessary to increase number of the patients enrolled to the study and followup the cardiac functions.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Çocuk · Doksorubisin · Natriüretik peptidler

Abstract

Antracyclines have been used for a wide variety of childhood solid tumors. Doxorubicin is the most common one used in pediatric oncology. Dose dependent cardiotoxicity is the major adverse effect of doxorubicin and may appear months or years after therapy. Serum BNP levels have been reported to have correlation with left ventricular dysfunction and may be used as a marker for doxorubicinduced cardiotoxicity. In this study, we detected cardiac functions of 22 children with solid tumors who had received cumulative doxorubicin doses of 120-450 mg/$m^2$ by echocardiography and detected the serum BNP levels. A correlation between serum BNP levels and cumulative doxorubicin dose was investigated. Serum BNP levels were found in the range of 0.70-3.00 ng/ml (mean; 1.34 ng/ml). The serum BNP levels in 10 children treated cumulative doxorubicin doses > 420 mg/m$m^2$ and in 12 children treated with cumulative doxorubicin levels between 120 and 360 mg/$m^2$ were in the range of 0.80-3.00 ng/ml (mean; 1.67 ng/ml) and 0.70-2.80 ng/ml (mean; 1.37 ng/ml) respectively. No correlation was found between the two groups. However, it was concluded that it is necessary to increase number of the patients enrolled to the study and followup the cardiac functions. The patients who have serum BNP concentrations above the mean levels of their groups should be closely followed up to define the potential role of blood BNP level to predict anthracycline induced cardiotoxicity in survivors of childhood cancer.

Özet

Doksorubisin, çocukluk dönemi solid tümörlerinin tedavisinde en sık kullanılan ilaçlardandır. En önemli yan etkisi, tedavi sırasında veya aylar ve yıllar sonra ortaya çıkabilen ve kümülatif 400-450 mg/$m^2$ nin üzerinde önemli derecede artış gösteren kardiyotoksisitedir. Sol ventrikül fonksiyon bozukluğu olan hastalarda, serum B tipi natriüretik peptid (BNP) düzeyinin kardiyak disfonksiyon derecesi için bir gösterge olabileceği ve gelişmekte olan patolojiyi erken düzeyde gösterebilecek bir belirteç olarak doksorubisin uygulanan hastalarda kullanılabileceği bildirilmektedir. Bu çalışmada, kümülatif 120-450 mg/$m^2$ doksorubisin tedavisi uygulanmış olan 22 solid tümörlü çocuğun kardiyak fonksiyonları ekokardiyografik olarak incelendi ve serum BNP düzeyleri saptandı. Serum BNP düzeyleri ile kümülatif doksorubisin dozu arasındaki ilişki araştırıldı. Serum BNP düzeyleri 0.70-3.00 ng/ml (ortalama; 1.34 ng/ml) aralığında saptandı. Kümülatif doksorubisin dozu 420 mg/$m^2$ ve üzerinde olan 10 hastanın serum BNP düzeyleri 0.80-3.00 ng/ml (ortalama; 1.67 ng/ml) aralığında, 120-360 mg/$m^2$ arasında olan 12 hastanın serum BNP düzeyleri 0.70-2.80 ng/ml (ortalama; 1.37 ng/ml) aralığında idi. Her iki grup serum BNP düzeyleri arasında istatistiksel olarak farklılık saptanmadı. Bununla birlikte olgu sayısının arttırılarak, geç dönemdeki kardiyak fonksiyonlar ile karşılaştırma yapılması, ortalamanın üzerinde serum BNP düzeyi saptanan hastaların geç dönemlerde gelişebilecek kardiyotoksisite yönünden daha yakından izlenmeleri gerektiği düşünülmektedir.

🔖

Cite This Article

KISMET, E., DEMİRKAYA, E., YURTTUTAN, N., BERBEROĞLU, S., KARADEMİR, S., AYDIN, H. İ., KALMAN, S., KÖSEOĞLU, V. (2004). Serum BNP levels in children treated with doxorubicin for their solid tumors. Gülhane Tıp Dergisi, Cilt: 46 - Sayı: 1, 38–42. https://ajindex.com/articles/225696

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Meadows, A.T., Hobbie, W.L.: The medical consequences of cure. Cancer 15: 524-528, 1986
  2. Riccardi, R., Lasorella, A., Mastrangelo, R. Principles of Cancer Chemotherapy in Children. In: Cancer in Children. Eds.: Voute, P.A., Kalifa, C., Barrett, A. 4th Edition, Oxford Med Public, 1998, p 44-59
  3. Allen, A.: The cardiotoxicity of Chemotherapetic Drugs. Seminars in Oncology 19: 529-542,1992
  4. Wilkins, M.R., Redondo, J., Brown, L.A.: The natriuretic peptide family. Lancet 349:1307-1310, 1997
  5. Nousiainen, T., Vanninen, E., Jantunen, E., Puustinen, J., Remes, J., Rantala, A., Vuolteenaho, O., Hartikainen, J.: Natriuretic peptides during the development of doxorubicininduced left ventricular diastolic dysfunction. J Intern Med 251; 228-234, 2002
  6. Hayakawa, H., Komada, Y., Hirayama, M., Hori, H., Ito, M., Sakurai,M.: Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 37; 4-9, 2001
  7. Greonlee, R.T., Murray, T., Bolden, S.; Wing PA: Cancer Statistics 2000. CA A Cancer Journal for Clinicians. 50;7-33, 2000
  8. Tolba, K.A., Deliargyris, E.N.: Cardiotoxicity of cancer therapy. Cancer Invest 17; 408-22, 1999
  9. Iacuone, J.J., Steinherz, L., Oblender, M.G., Bornard, D.R.: Modifications For Toxicity In: Supportive Care of Children with Cancer Ed.: Ablin AR. 2nd edition The Johns Hopkins University Press, 1997, 79-109
  10. Herman, E.H., Zhang, J., Lipshultz, S.E., Rifai, N., Chadwick, D., Takeda, K., Yu, Z.X., Ferrans, V.J.: Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17;2237-2243, 1999
  11. Steinherz, L.J., Graham, T., Hurwitz, R., Sondheimer, H.M., Schwartz, R.G., Shaffer, E.M., Sandor, G., Benson, L., Williams, R.: Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 89; 942-949, 1992
  12. Christenson, R.H., Duh, S.H. Evidence based approach to practice guides and decision thresholds for cardiac markers. Scand J Clin Lab Invest Suppl 230: 90-102, 1999
  13. Naruse, M., Takeyama, Y., Tanabe, A., Hiroshige, J., Naruse, K., Yoshimoto, T., Tanaka, 42 M., Katagiri, T., Demura, H.: Atrial and brain natriuretic peptides in cardiovascular diseases. Hypertension 23; 1231-1234, 1994
  14. Cowie, M.R., Struthers, A.D., Wood, D.A., Coats, A.J., Thompson, S.G.